BioClavis has announced the planned creation of 43 new jobs with a £10.5 million investment supported by Scottish Enterprise.
Bioclavis is a new spin-out from Californian molecular profiling company Biospyder, to be based at the Clinical Innovation Zone at Glasgow’s Queen Elizabeth University Hospital, creating 43 new jobs.
BioSpyder’s investment has been supported by a £4.5m Seek & Solve research and development grant from Scottish Enterprise. It forms part of a total investment of £10.5m, which will see BioClavis adapt BioSpyder’s TempO-Seq platform technology into a novel diagnostic tool for precision medicine in a number of high value clinical indications, in close collaboration with the health service and university researchers.
Joel McComb, CEO of BioSpyder and BioClavis said: “We’re very excited to build on the success we’ve had in other molecular profiling applications and bring this novel method to bear on discovery and deployment of next generation genomic diagnostics.
“We determined Glasgow, Scotland to be the ideal location for this initiative based in large part on the support and close working relationships with Scottish Enterprise, NHS and the University.”
We have launched online data tools to put the city firmly on the map for business relocation, investment and...Read More
A major new television and film studio is set to be created in the centre of Glasgow. Glasgow City...Read More
Property development and investment firm Osborne+Co has achieved planning consent from Glasgow City Council to deliver a £100 million mixed-use transformation of the...Read More
The University of Glasgow has been named Times Higher Education (THE) University of the Year. Glasgow’s work to redress its...Read More
Sign-up to our email updates for the latest investment opportunities and information in Glasgow. Fill out the form below with your email.
